



Challenges, Limitations and Advancement of Vaccines and Adjuvants

Guest Editor:

Prof. Dr. Cheol-Heui Yun

Department of Agricultural
Biotechnology, College of
Agriculture and Life Sciences,
Seoul National University, Seoul
08826, Korea

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues and Friends,

Vaccination is a process of introducing foreign antigenic (better with immunogenic) epitopes to target host in a form of whole bacteria or viruses (inactivated or attenuated), proteins, or nucleotides to eventually induce protective memory responses in the host. Adjuvant is essentially required to improve the efficacy of vaccine via enhancing the host immune responses. The main action mechanism of the adjuvants is to improve immunogenicity of antigen presenting cells to induce memory responses in T cells and B cells, resulting in a long-term protection against target pathogen. The current Special issue entitled 'Challenges, limitations and advancement of vaccines and adjuvants' focuses on the platform and technologies (i.e., material science and synthetic biology), target delivery, and a formulation of vaccine and adjuvant, maximizing their protective immune responses, and validation of the vaccines. Furthermore, the articles in relation to future prospecting, preparedness, efficacy, reactogenicity, validation and advancement of vaccines and adjuvants together with their limitations and challenges are all welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com